<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="906">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610567</url>
  </required_header>
  <id_info>
    <org_study_id>36746020.5.1001.0068</org_study_id>
    <nct_id>NCT04610567</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)</brief_title>
  <acronym>Nano-COVID19</acronym>
  <official_title>Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Santa Marcelina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a prospective, randomized, double-blind, placebo-controlled study,&#xD;
      conducted in two phases. The purpose of the study is to evaluate the safety and efficacy of&#xD;
      methotrexate in a cholesterol-rich non-protein nanoparticle (MTX -LDE) in adults diagnosed&#xD;
      with mild Coronavirus-19(COVID-19) disease.&#xD;
&#xD;
      A total of 100 patients will be randomized to receive MTX-LDE or placebo each 7 days, up to 3&#xD;
      times, during in hospital treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of (MTX -LDE) in patients&#xD;
      with mild Coronavirus-19 (COVID-19) disease.&#xD;
&#xD;
      In phase 1, firstly 3 patients with moderate COVID-19 disease will receive MTX-LDE IV 15mg&#xD;
      each 7 days, up to 3 times, during hospitalization. After that, 9 patients with moderate&#xD;
      COVID-19 disease will receive MTX-LDE IV 30mg each 7 days, up to 3 times, during&#xD;
      hospitalization. Follow-up assessments will occur daily following randomization during in&#xD;
      hospital treatment and 2 weeks after discharge for evaluation of the occurrence of adverse&#xD;
      events.The purpose of this phase will be evaluate safety and pharmacokinetics.&#xD;
&#xD;
      If no objection by data and safety monitoring board (DSMB), will be authorized to start the&#xD;
      second phase.&#xD;
&#xD;
      In phase 2, 88 patients with moderate COVID-19 disease will be randomized to receive MTX-LDE&#xD;
      IV 30mg or placebo-LDE IV each 7 days, up to 3 times, during hospitalization. Follow-up&#xD;
      assessments will occur daily following randomization during in hospital treatment and 2 weeks&#xD;
      after discharge for evaluation of the occurrence of any trial endpoints or other adverse&#xD;
      events.The primary endpoint of this phase will be reduction in duration of hospitalization&#xD;
      stay between groups.&#xD;
&#xD;
      Patients will undergo clinical and laboratory safety evaluations daily. An algorithm for drug&#xD;
      suspension based on clinical and laboratory finding will be followed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized, double-blind, placebo-controlled, multi-center study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Compare the duration of hospital stay between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring mechanical ventilation</measure>
    <time_frame>15 days after randomization</time_frame>
    <description>The secondary outcome is the need for mechanical ventilation between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring vasoactive drugs</measure>
    <time_frame>15 days after randomization</time_frame>
    <description>The secondary outcome is the need for vasoactive drugs between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring renal replacement therapy</measure>
    <time_frame>15 days after randomization</time_frame>
    <description>The secondary outcome is the need for renal replacement therapy between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary infection</measure>
    <time_frame>15 days after randomization</time_frame>
    <description>The secondary outcome is the incidence of secondary infection between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>Baseline and change from baseline to 15 days after randomization</time_frame>
    <description>The secondary outcome is the comparison of Sequential Organ Failure Assessment (SOFA) score between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization (WHO) COVID-19 score</measure>
    <time_frame>Baseline and change from baseline to 15 days after randomization</time_frame>
    <description>The secondary outcome is the comparison of World Health Organization (WHO) COVID-19 clinical score between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>Baseline and change from baseline to 15 days after randomization</time_frame>
    <description>The secondary outcome is the comparison of IL-6 levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimer-D</measure>
    <time_frame>Baseline and change from baseline to 15 days after randomization</time_frame>
    <description>The secondary outcome is the comparison of dimer-D levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest CT scan</measure>
    <time_frame>Baseline and change from baseline to 15 days after randomization</time_frame>
    <description>The secondary outcome is the comparison of chest CT scan between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of laboratory alterations</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>The secondary outcome is the comparison of red blood cells; white blood cells;Platelets; Urea;Creatinine levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical side effects</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Compare the incidence of clinical significant symptoms (new and persistent stomatitis, vomiting, diarrhea, alopecia, neurotoxicity, bradycardia, hypotension, local pain) reported between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other adverse events</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Compare the incidence of other adverse events (not expected) between groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronavirus</condition>
  <condition>Inflammation</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>MTX-LDE phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate carried by a lipid nanoparticle (MTX-LDE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX-LDE phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate carried by a lipid nanoparticle (MTX-LDE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-LDE phase 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lipid nanoparticle (LDE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate-LDE phase 1</intervention_name>
    <description>3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .&#xD;
All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE</description>
    <arm_group_label>MTX-LDE phase 1</arm_group_label>
    <other_name>MTX-LDE phase 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate-LDE phase 2</intervention_name>
    <description>44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE</description>
    <arm_group_label>MTX-LDE phase 2</arm_group_label>
    <other_name>MTX-LDE phase 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-LDE phase 2</intervention_name>
    <description>44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE</description>
    <arm_group_label>Placebo-LDE phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were hospitalized with confirmed COVID-19&#xD;
&#xD;
          -  Mild Coronavirus-19 disease (WHO Coronavirus-19 scale &lt; 5)&#xD;
&#xD;
          -  Fewer than 14 days since symptom onset.&#xD;
&#xD;
          -  Female patient is not of childbearing potential, defined as postmenopausal for at&#xD;
             least 1 year or surgically sterile.&#xD;
&#xD;
          -  Female patient is of childbearing potential must has a negative pregnancy test.&#xD;
&#xD;
          -  Signing the study informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for oxygen supplementation &gt;4 L/min via nasal cannula or ≥40% via Venturi mask.&#xD;
&#xD;
          -  Need for oxygen supplementation via high-flow nasal cannula.&#xD;
&#xD;
          -  Need for invasive mechanical ventilation.&#xD;
&#xD;
          -  Extent of pulmonary involvement &gt; 50% by CT scan.&#xD;
&#xD;
          -  Chronic renal failure (estimated glomerular filtration rate &lt;30 mL/min/1.73 m2)&#xD;
&#xD;
          -  History of liver cirrhosis (Bilirubins levels &gt; 3mg/dl)&#xD;
&#xD;
          -  History of heart failure ( Ejection fraction &lt;40%)&#xD;
&#xD;
          -  History of Steven-Johnson disease&#xD;
&#xD;
          -  History of stroke in the last 6 months&#xD;
&#xD;
          -  History of sickle cell disease&#xD;
&#xD;
          -  Chronic use of oral steroid therapy or other immunosuppressive or biologic response&#xD;
             modifiers.&#xD;
&#xD;
          -  Prior history of chronic hepatitis B or C infection and known HIV positive.&#xD;
&#xD;
          -  Patient undergoing chemotherapy for cancer&#xD;
&#xD;
          -  Sepsis caused by fungal or multidrug resistant gram-negative bacteria&#xD;
&#xD;
          -  Known allergy to methotrexate.&#xD;
&#xD;
          -  Body mass index(BMI) &gt; 40 or &lt;18.5&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Patients enrolled in other clinical trials in the last 12 months&#xD;
&#xD;
          -  Patient is considered by the investigator, for any reason, to be an unsuitable&#xD;
             candidate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raul Maranhão, MD;PhD</last_name>
    <phone>+551126615951</phone>
    <email>raul.maranhao@incor.usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Institute (InCor) - University of São Paulo Medical School, São Paulo, Brazil</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Marinho, MD</last_name>
      <phone>+5511948045001</phone>
      <email>lucaslage@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Salvador Oliveira, MD;PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute Prevent Senior</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodrigo Esper, MD;PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://www.who.int/docs/default-source/blue-print/covid-19-therapeutic-trial-synopsis.pdf?sfvrsn=44b83344_1&amp;download=true.</url>
    <description>WHO COVID-19 Therapeutic Trial Synopsis</description>
  </link>
  <reference>
    <citation>Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020 Jul 7;142(1):68-78. doi: 10.1161/CIRCULATIONAHA.120.047549. Epub 2020 Apr 15.</citation>
    <PMID>32293910</PMID>
  </reference>
  <reference>
    <citation>Solinas C, Perra L, Aiello M, Migliori E, Petrosillo N. A critical evaluation of glucocorticoids in the management of severe COVID-19. Cytokine Growth Factor Rev. 2020 Aug;54:8-23. doi: 10.1016/j.cytogfr.2020.06.012. Epub 2020 Jun 24. Review.</citation>
    <PMID>32616381</PMID>
  </reference>
  <reference>
    <citation>Vinciguerra M, Romiti S, Fattouch K, De Bellis A, Greco E. Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm. J Clin Med. 2020 Jul 3;9(7). pii: E2095. doi: 10.3390/jcm9072095. Review.</citation>
    <PMID>32635302</PMID>
  </reference>
  <reference>
    <citation>Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig. 2020 Jun;40(6):511-518. doi: 10.1007/s40261-020-00917-3. Review.</citation>
    <PMID>32337664</PMID>
  </reference>
  <reference>
    <citation>Barbieri LR, Lourenço-Filho DD, Tavares ER, Carvalho PO, Gutierrez PS, Maranhão RC, Stolf NAG. Influence of Drugs Carried in Lipid Nanoparticles in Coronary Disease of Rabbit Transplanted Heart. Ann Thorac Surg. 2017 Aug;104(2):577-583. doi: 10.1016/j.athoracsur.2016.12.044. Epub 2017 Mar 24.</citation>
    <PMID>28347533</PMID>
  </reference>
  <reference>
    <citation>Bulgarelli A, Leite AC Jr, Dias AA, Maranhão RC. Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits. Cardiovasc Drugs Ther. 2013 Dec;27(6):531-9. doi: 10.1007/s10557-013-6488-3.</citation>
    <PMID>24065615</PMID>
  </reference>
  <reference>
    <citation>Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012 Apr;59(4):308-14. doi: 10.1097/FJC.0b013e318241c385.</citation>
    <PMID>22113347</PMID>
  </reference>
  <reference>
    <citation>Maranhão RC, Tavares ER. Advances in non-invasive drug delivery for atherosclerotic heart disease. Expert Opin Drug Deliv. 2015 Jul;12(7):1135-47. doi: 10.1517/17425247.2015.999663. Epub 2015 Jan 14. Review.</citation>
    <PMID>25585820</PMID>
  </reference>
  <reference>
    <citation>Maranhão RC, Guido MC, de Lima AD, Tavares ER, Marques AF, Tavares de Melo MD, Nicolau JC, Salemi VM, Kalil-Filho R. Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats. Int J Nanomedicine. 2017 May 17;12:3767-3784. doi: 10.2147/IJN.S129324. eCollection 2017.</citation>
    <PMID>28553113</PMID>
  </reference>
  <results_reference>
    <citation>Shah A, Kashyap R, Tosh P, Sampathkumar P, O'Horo JC. Guide to Understanding the 2019 Novel Coronavirus. Mayo Clin Proc. 2020 Apr;95(4):646-652. doi: 10.1016/j.mayocp.2020.02.003. Epub 2020 Feb 28.</citation>
    <PMID>32122636</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.</citation>
    <PMID>32007143</PMID>
  </results_reference>
  <results_reference>
    <citation>Mitchell WB. Thromboinflammation in COVID-19 acute lung injury. Paediatr Respir Rev. 2020 Sep;35:20-24. doi: 10.1016/j.prrv.2020.06.004. Epub 2020 Jun 11. Review.</citation>
    <PMID>32653469</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou Z, Guo D, Li C, Fang Z, Chen L, Yang R, Li X, Zeng W. Coronavirus disease 2019: initial chest CT findings. Eur Radiol. 2020 Aug;30(8):4398-4406. doi: 10.1007/s00330-020-06816-7. Epub 2020 Mar 24.</citation>
    <PMID>32211963</PMID>
  </results_reference>
  <results_reference>
    <citation>Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996 Dec;39(12):1951-60. Review.</citation>
    <PMID>8961899</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Raul Cavalcante Maranhão</investigator_full_name>
    <investigator_title>MD; PHD. Director Lipid Metabolism Laboratory, Heart Institute</investigator_title>
  </responsible_party>
  <keyword>coronavirus</keyword>
  <keyword>inflammation</keyword>
  <keyword>nanoparticles</keyword>
  <keyword>methotrexate</keyword>
  <keyword>covid19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

